Literature DB >> 2941294

Ciprofloxacin in the treatment of urinary tract infection in patients with multiple sclerosis.

H Van Poppel, M Wegge, H Dammekens, V Chysky.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2941294     DOI： 10.1007/bf02014002

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN： 0722-2211            Impact factor:   3.267


× No keyword cloud information.
  9 in total

1.  [Microbiological approach to urinary infections with Pseudomonas aeruginosa].

Authors:  A Leruitte; C Godard; J Beumer
Journal:  Acta Urol Belg       Date:  1979-10

2.  Pharmacokinetics and tissue penetration of ciprofloxacin.

Authors:  B Crump; R Wise; J Dent
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

3.  Neuro-muscular dysfunction of the lower urinary tract in multiple sclerosis.

Authors:  H Van Poppel; R L Vereecken; A Leruitte
Journal:  Paraplegia       Date:  1983-12

4.  Activity of ciprofloxacin (BAYo 9867) against Pseudomonas aeruginosa and ampicillin-resistant Enterobacteriaceae.

Authors:  C Roy; A Foz; C Segura; M Tirado; M Teixell; D Teruel
Journal:  Infection       Date:  1983 Nov-Dec       Impact factor: 3.553

5.  The in vitro and in vivo activity of ciprofloxacin.

Authors:  H J Zeiler; K Grohe
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

6.  In vitro activity of ciprofloxacin (Bay o 9867).

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

7.  Comparative activities of ciprofloxacin (Bay o 9867), norfloxacin, pipemidic acid, and nalidixic acid.

Authors:  H L Muytjens; J van der Ros-van de Repe; G van Veldhuizen
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

8.  In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid.

Authors:  A Bauernfeind; C Petermüller
Journal:  Eur J Clin Microbiol       Date:  1983-04       Impact factor: 3.267

9.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191
  9 in total
  5 in total

Review 1.  Clinical experience with ciprofloxacin in the treatment of urinary tract infections: a review.

Authors:  H van Poppel; V Chyský; R Hullmann; L Baert
Journal:  Infection       Date:  1988       Impact factor: 3.553

2.  Use of ciprofloxacin versus use of aminoglycosides for therapy of complicated urinary tract infection: prospective, randomized clinical and pharmacokinetic study.

Authors:  G D Fang; C Brennen; M Wagener; D Swanson; M Hilf; L Zadecky; J DeVine; V L Yu
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

3.  Efficacy and safety of oral ciprofloxacin for treatment of serious urinary tract infections.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

Review 4.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

Review 5.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.